
- Volume 0 0
Occupational Therapy Is Not Effective in Early RA
Occupational therapy does not serve any functional benefits for individuals in the early stages of rheumatoid arthritis (RA), suggest the results of a study published in the Annals of the Rheumatic Diseases (January 2004). A goal of occupational therapy for RA is to help patients maintain hand function. Although this type of therapy has been shown to be helpful in people who have had RA for 8 to 10 years, it is uncertain whether this type of intervention is beneficial to patients in the early stages.
Even with the uncertainty, there has been action toward giving occupational therapy and education to patients with early RA, the report said. To investigate the effectiveness of such a strategy, the researchers studied 300 participants who had been diagnosed with RA for <2.5 years. The participants were randomly assigned to receive conventional treatment with or without occupational therapy. On average, the participants in the occupational therapy group received >7 hours of such therapy.
At the end of the 2-year study, participants in the occupational therapy group were more apt to "selfmanage" their disease. The researchers, however, did not see any significant differences between the groups in terms of health status. They suggest several explanations, such as that the medications used to treat RA may have "erased" any of the positive benefits of occupational therapy early in the RA process.
Articles in this issue
over 21 years ago
Interface Speeds Up Prescription Fillingover 21 years ago
New Technologies Top Surveyover 21 years ago
Partnership Addresses Packaging Solutionsover 21 years ago
PDX Software Gets High Marksover 21 years ago
Polar Powder Cold Pak with Magnetic Therapyover 21 years ago
Seal•ONover 21 years ago
SaltAire Sinus Reliefover 21 years ago
Zim's Crack Creme Hand Sanitizerover 21 years ago
CoroWise Plant Sterolsover 21 years ago
CulturelleNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.